Roivant, a biopharmaceutical company, has entered a definitive agreement with Roche to acquire Telavant Holdings, Inc., a Roivant company owned by Roivant Sciences Ltd. and Pfizer Inc. The agreement includes the development, manufacturing, and commercialization rights in the US and Japan for RVT-3101, a TL1A-directed antibody used in treating inflammatory bowel disease.
Under the terms of the agreement, Roche will pay $7.1 billion upfront and a near-term milestone payment of $150 million. Roche will gain full rights to further develop, manufacture, and commercialize RVT-3101 in the US and Japan, with Pfizer holding commercialization rights outside these regions. Roche plans to initiate a global Phase 3 trial for RVT-3101 to expedite its availability for patients with inflammatory bowel disease.
RVT-3101 has shown promise in the TUSCANY-2 phase 2b study, demonstrating improved clinical remission and endoscopic improvement in patients with moderate to severe ulcerative colitis. The antibody targets both inflammation and fibrosis, potentially making it applicable to multiple diseases.
The acquisition aligns with Roche’s commitment to advancing therapies that make a significant difference for patients, particularly those with inflammatory bowel disease. The transaction is subject to regulatory approvals and is expected to close in Q4 2023 or Q1 2024.
The deal also includes an option for Roche to enter a global collaboration with Pfizer on a next-generation p40/TL1A-directed bispecific antibody currently in Phase 1.
The acquisition reflects Roivant’s mission to accelerate the development and commercialization of impactful medicines and create value for patients and shareholders.
